ReviewAnnual review of pharmacology and toxicology2021
Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities.
Review in Annual review of pharmacology and toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Gastric bacterial microbiota and gastric carcinogenesis: from dysbiosis to immune remodeling and therapeutic opportunities.Frontiers in immunology · 2026Review
- The gut microbiome in colorectal anastomotic leakage: from mechanisms to precision.Frontiers in medicine · 2026Review
- Order among chaos: High throughput MYCroplanters can distinguish interacting drivers of host infection in a highly stochastic system.PLoS pathogens · 2025Article
- Gut Microbiota in Ischemic Stroke: Role of Gut Bacteria-Derived Metabolites.Translational stroke research · 2023Review
- Dysbiosis and primary B-cell immunodeficiencies: current knowledge and future perspective.Immunologic research · 2023Review
- Enabling technology and core theory of synthetic biology.Science China. Life sciences · 2023Review
- A data-driven approach for predicting the impact of drugs on the human microbiome.Nature communications · 2023Article
- Review
- Closely related Salmonella Derby strains triggered distinct gut microbiota alteration.Gut pathogens · 2022Article
- Machine Learning Predicts Drug Metabolism and Bioaccumulation by Intestinal Microbiota.Pharmaceutics · 2021Article
- Engineering Host Microbiome for Crop Improvement and Sustainable Agriculture.Frontiers in microbiology · 2021Review
- Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the past decade of microbiome research, we have learned about numerous adverse interactions between the microbiome and medical interventions such as drugs, radiation, and surgery. What if we could alter our microbiomes to prevent these events? In this review, we discuss potential routes to mitigate microbiome adverse events, including applications from the emerging field of microbiome engineering. We highlight cases where the microbiome acts directly on a treatment, such as via differential drug metabolism, and cases where a treatment directly harms the microbiome, such as in radiation therapy. Understanding and preventing microbiome adverse events is a difficult challenge that will require a data-driven approach involving causal statistics, multiomics techniques, and a personalized means of mitigating adverse events. We propose research considerations to encourage productive work in preventing microbiome adverse events, and we highlight the many challenges and opportunities that await.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.